Journal article

Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)

G Kong, M Thompson, M Collins, A Herschtal, MS Hofman, V Johnston, P Eu, M Michael, Rodney J Hicks

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | SPRINGER | Published : 2014

Abstract

PURPOSE: To review the response and outcomes of (177)Lu-DOTA-octreotate chemoradionuclide therapy (LuTate PRCRT) in patients with neuroendocrine tumour (NET) expressing high levels of somatostatin receptors with uncontrolled symptoms or disease progression. METHODS: A total of 68 patients (39 men; 17 - 76 years of age) who had completed an induction course of at least three cycles of LuTate PRCRT between January 2006 and June 2010 were reviewed. Ten patients were treated for uncontrolled symptoms and 58 had disease progression despite conventional treatment. The majority had four induction LuTate cycles (median treatment duration 5 months and cumulative activity 31 GBq), and 63 patients had ..

View full abstract